CClinicalTrials.gg
Not yet recruitingNCT07357350Updated Jan 22, 2026

Effectiveness of Pain Management Interventions in Patients With Abdominal and Pelvic Cancer

An observational study in Abdominal Cancer, sponsored by Aga Khan University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Aga Khan University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this prospective observational study is to observe the effectiveness of pain management interventions in patients with abdominal and pelvic cancer pain.

The main question[s] it aims to answer are:

  • The effectiveness of pain management interventions.
  • The frequency of pain intervention procedures and side effects and complications of pain management interventions
02

Conditions studied

  • Abdominal Cancer
03

In context

Lead sponsor

Aga Khan University is the lead sponsor of 290 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with chronic pain due to abdominal and pelvic cancer.

Inclusion criteria

  • Patients with chronic pain due to abdominal and pelvic cancer
  • Both Male and Female
  • Ages18-65 years
  • Patients who with recurrence or metastasis

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse to give consent
  • Patients who were lost to follow up after initial visit or assessment
  • History of severe depression or psychiatric illness
  • History of surgical procedure due to cancer
  • Patients with DNR code
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Patient reported NRS score

    Numeric Rating Score from 0 (no pain)- 10 (severe pain)

    Time frame: First visit and then at 3 months

Secondary outcomes

  1. Number of patients

    Number of patients on whom the intervention is performed.

    Time frame: From 2 weeks to 3 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07357350
Lead sponsor
Aga Khan University
Responsible party
Ali Sarfraz Siddiqui (Associate Professor, Aga Khan University) — Principal investigator
First posted
Jan 22, 2026
Start date
Jan 16, 2026 (estimated)
Primary completion
Oct 15, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 22, 2026

Study contacts

Ali Sarfraz Siddiqui, MBBS, FCPS
Contact
sarfraz.siddiqui@aku.edu
00922134864397 ext. 4397

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion